 | Frank Leebeek, MD, PhD obtained his medical degree from the Erasmus University in Rotterdam, the Netherlands in 1990. He earned his PhD degree on clinical studies on fibrinolysis inhibitors synthesized by the liver also at the Erasmus University. He subsequently worked as a post-doctoral fellow for two years at the University of North Carolina in Chapel Hill, USA to study structure function of the interleukin-6 and fibrinogen synthesis. He was trained as a haematologist at the Erasmus University Medical Center in Rotterdam, where he was appointed full professor in 2009. He is currently head of the department of Haematology. He is coordinating a research team on Haemostasis and Thrombosis with several research topics. This includes inherited bleeding disorders, especially von Willebrand disease and haemophilia, such as gene therapy studies in haemophilia B. He is the principal investigator of the Willebrand in the Netherlands (WiN) study. In addition, he investigates the etiology and management of abdominal vein thrombosis and the role of coagulation in the pathogenesis of arterial thrombosis.
He has been secretary of the Dutch Society of Thrombosis and Haemostasis, chairman of the Dutch Haemophilia doctors organisation, and is currently a board member of the Dutch Society of Haematology. He is co-chair of the SSC on von Willebrand Factor of the ISTH. Dr Leebeek has (co-)authored 286 scientific publications listed in PubMed, 20 book chapters and contributed to Dutch treatment guidelines on haemophilia, von Willebrand’s disease and venous thrombosis.
|
